567 Results

People

  1. Motzer
    Motzer
  2. Horwitz
    Horwitz
  3. Riely
    Riely
  4. Zelenetz
    Zelenetz
  5. Kris
    Kris
  6. Postow
    Postow
  7. Rusch
    Rusch
  8. Wolchok
    Wolchok
  9. Bains
    Bains
  10. Giralt
    Giralt

Groups

  1. Department of Medicine (349)
  2. Solid Tumor Oncology Division (186)
  3. Hematologic Malignancies, Division of (140)
  4. Center for Hematologic Malignancies (120)
  5. Survivorship Research (74)
  6. Surgery (72)
  7. Division of Subspecialty Medicine (66)
  8. GSK Faculty (53)
  9. Thoracic Oncology (53)
  10. Lymphoma (48)
  1. "pneumonia"
Formats
  1. Journal Article (509)
  2. Review (36)
  3. Research Letter (5)
  4. Book Section (4)
  5. Editorial (4)
  6. Correspondence (3)
  7. Guidelines (3)
  8. Conference Paper (1)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (349)
  2. Solid Tumor Oncology Division (186)
  3. Hematologic Malignancies, Division of (140)
  4. Center for Hematologic Malignancies (120)
  5. Survivorship Research (74)
  6. Surgery (72)

More Groups

People
  1. Robert Motzer (24)
  2. Jedd Wolchok (16)
  3. Steven Horwitz (15)
  4. Andrew Zelenetz (14)
  5. Gregory Riely (14)
  6. Mark Kris (12)

More People

Years
  1. 2025 (27)
  2. 2024 (54)
  3. 2023 (48)
  4. 2022 (24)
  5. 2021 (20)
  6. 2020 (40)

More Years

Publications
  1. Journal of Clinical Oncology (34)
  2. Lancet Oncology (23)
  3. Cancer (17)
  4. Blood (16)
  5. Journal of Thoracic Oncology (14)
  6. Blood Advances (13)

More Publications

Publishers
  1. Elsevier Inc. (105)
  2. Elsevier Science, Inc. (49)
  3. Springer (36)
  4. American Society of Clinical Oncology (35)
  5. Nature Publishing Group (35)
  6. Oxford University Press (34)

More Publishers

Results (567)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ceftolozane-tazobactam in the treatment of experimental Pseudomonas aeruginosa pneumonia in persistently neutropenic rabbits: Impact on strains with genetically defined mechanisms of resistance
    Journal Article

    Petraitis, V.; Petraitiene, R.; Naing, E.; Aung, T.; Thi, W. P.; Kavaliauskas, P.; Maung, B. B. W.; Michel, A. O.; Ricart Arbona, R. J.; DeRyke, A. C.; more...
    Antimicrobial Agents and Chemotherapy (2019)

    Fulltext@MSK | Save
  • Targeted therapies for myeloproliferative neoplasms
    Review

    Li, B.; Rampal, R. K.; Xiao, Z.
    Biomarker Research (2019)

    Fulltext@MSK | Save
  • Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: The phase II GATHER study
    Journal Article

    Sharman, J. P.; Forero-Torres, A.; Costa, L. J.; Flinn, I. W.; Inhorn, L.; Kelly, K.; Bessudo, A.; Fayad, L. E.; Kaminski, M. S.; Evens, A. M.; more...
    Leukemia and Lymphoma (2019)

    Fulltext@MSK | Save
  • Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
    Journal Article

    Leighl, N. B.; Hellmann, M. D.; Hui, R.; Carcereny, E.; Felip, E.; Ahn, M. J.; Eder, J. P.; Balmanoukian, A. S.; Aggarwal, C.; Horn, L.; more...
    The Lancet Respiratory Medicine (2019)

    Fulltext@MSK | Save
  • Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study
    Journal Article

    Trudel, S.; Lendvai, N.; Popat, R.; Voorhees, P. M.; Reeves, B.; Libby, E. N.; Richardson, P. G.; Hoos, A.; Gupta, I.; Bragulat, V.; more...
    Blood Cancer Journal (2019)

    Fulltext@MSK | Save
  • Early outcomes of breast cancer patients treated with post-mastectomy uniform scanning proton therapy
    Journal Article

    Luo, L.; Cuaron, J.; Braunstein, L.; Gillespie, E.; Kahn, A.; McCormick, B.; Mah, D.; Chon, B.; Tsai, H.; Powell, S.; more...
    Radiotherapy and Oncology (2019)

    Fulltext@MSK | Save
  • Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: A phase 1/2a study
    Journal Article

    Younes, A.; Brody, J.; Carpio, C.; Lopez-Guillermo, A.; Ben-Yehuda, D.; Ferhanoglu, B.; Nagler, A.; Ozcan, M.; Avivi, I.; Bosch, F.; more...
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study
    Journal Article

    Gupta, V.; Kosiorek, H. E.; Mead, A.; Klisovic, R. B.; Galvin, J. P.; Berenzon, D.; Yacoub, A.; Viswabandya, A.; Mesa, R. A.; Goldberg, J.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: Post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503)
    Journal Article

    Altorki, N. K.; Wang, X.; Wigle, D.; Gu, L.; Darling, G.; Ashrafi, A. S.; Landrenau, R.; Miller, D.; Liberman, M.; Jones, D. R.; more...
    The Lancet Respiratory Medicine (2018)

    Fulltext@MSK | Save
  • CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes
    Journal Article

    de Lima, M.; Oran, B.; Champlin, R. E.; Papadopoulos, E. B.; Giralt, S. A.; Scott, B. L.; William, B. M.; Hetzer, J.; Laille, E.; Hubbell, B.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save